Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts

Cytokines such as tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) can induce apoptosis in colon cancer cells through engagement of death receptors. Nevertheless, evading apoptosis induced by anticancer drugs characterizes many types of cancers. This results in the need for combinatio...

Full description

Saved in:
Bibliographic Details
Published inMolecular cancer therapeutics Vol. 6; no. 9; pp. 2591 - 2599
Main Authors Psahoulia, Faiy H, Drosopoulos, Konstantinos G, Doubravska, Lenka, Andera, Ladislav, Pintzas, Alexander
Format Journal Article
LanguageEnglish
Published United States American Association for Cancer Research 01.09.2007
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Cytokines such as tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) can induce apoptosis in colon cancer cells through engagement of death receptors. Nevertheless, evading apoptosis induced by anticancer drugs characterizes many types of cancers. This results in the need for combination therapy. In this study, we have investigated whether the flavonoid quercetin could sensitize human colon adenocarcinoma cell lines to TRAIL-induced apoptosis. We report that quercetin enhanced TRAIL-induced apoptosis by causing the redistribution of DR4 and DR5 into lipid rafts. Nystatin, a cholesterol-sequestering agent, prevented quercetin-induced clustering of death receptors and sensitization to TRAIL-induced apoptosis in colon adenocarcinoma cells. In addition, our experiments show that quercetin, in combination with TRAIL, triggered the mitochondrial-dependent death pathway, as shown by Bid cleavage and the release of cytochrome c to the cytosol. Together, our findings propose that quercetin, through its ability to redistribute death receptors at the cell surface, facilitates death-inducing signaling complex formation and activation of caspases in response to death receptor stimulation. Based on these results, this study provides a challenging approach to enhance the efficiency of TRAIL-based therapies. [Mol Cancer Ther 2007;6(9):2591–9]
AbstractList Abstract Cytokines such as tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) can induce apoptosis in colon cancer cells through engagement of death receptors. Nevertheless, evading apoptosis induced by anticancer drugs characterizes many types of cancers. This results in the need for combination therapy. In this study, we have investigated whether the flavonoid quercetin could sensitize human colon adenocarcinoma cell lines to TRAIL-induced apoptosis. We report that quercetin enhanced TRAIL-induced apoptosis by causing the redistribution of DR4 and DR5 into lipid rafts. Nystatin, a cholesterol-sequestering agent, prevented quercetin-induced clustering of death receptors and sensitization to TRAIL-induced apoptosis in colon adenocarcinoma cells. In addition, our experiments show that quercetin, in combination with TRAIL, triggered the mitochondrial-dependent death pathway, as shown by Bid cleavage and the release of cytochrome c to the cytosol. Together, our findings propose that quercetin, through its ability to redistribute death receptors at the cell surface, facilitates death-inducing signaling complex formation and activation of caspases in response to death receptor stimulation. Based on these results, this study provides a challenging approach to enhance the efficiency of TRAIL-based therapies. [Mol Cancer Ther 2007;6(9):2591–9]
Cytokines such as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis in colon cancer cells through engagement of death receptors. Nevertheless, evading apoptosis induced by anticancer drugs characterizes many types of cancers. This results in the need for combination therapy. In this study, we have investigated whether the flavonoid quercetin could sensitize human colon adenocarcinoma cell lines to TRAIL-induced apoptosis. We report that quercetin enhanced TRAIL-induced apoptosis by causing the redistribution of DR4 and DR5 into lipid rafts. Nystatin, a cholesterol-sequestering agent, prevented quercetin-induced clustering of death receptors and sensitization to TRAIL-induced apoptosis in colon adenocarcinoma cells. In addition, our experiments show that quercetin, in combination with TRAIL, triggered the mitochondrial-dependent death pathway, as shown by Bid cleavage and the release of cytochrome c to the cytosol. Together, our findings propose that quercetin, through its ability to redistribute death receptors at the cell surface, facilitates death-inducing signaling complex formation and activation of caspases in response to death receptor stimulation. Based on these results, this study provides a challenging approach to enhance the efficiency of TRAIL-based therapies.
Cytokines such as tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) can induce apoptosis in colon cancer cells through engagement of death receptors. Nevertheless, evading apoptosis induced by anticancer drugs characterizes many types of cancers. This results in the need for combination therapy. In this study, we have investigated whether the flavonoid quercetin could sensitize human colon adenocarcinoma cell lines to TRAIL-induced apoptosis. We report that quercetin enhanced TRAIL-induced apoptosis by causing the redistribution of DR4 and DR5 into lipid rafts. Nystatin, a cholesterol-sequestering agent, prevented quercetin-induced clustering of death receptors and sensitization to TRAIL-induced apoptosis in colon adenocarcinoma cells. In addition, our experiments show that quercetin, in combination with TRAIL, triggered the mitochondrial-dependent death pathway, as shown by Bid cleavage and the release of cytochrome c to the cytosol. Together, our findings propose that quercetin, through its ability to redistribute death receptors at the cell surface, facilitates death-inducing signaling complex formation and activation of caspases in response to death receptor stimulation. Based on these results, this study provides a challenging approach to enhance the efficiency of TRAIL-based therapies. [Mol Cancer Ther 2007;6(9):2591–9]
Author Lenka Doubravska
Alexander Pintzas
Ladislav Andera
Faiy H. Psahoulia
Konstantinos G. Drosopoulos
Author_xml – sequence: 1
  givenname: Faiy H
  surname: Psahoulia
  fullname: Psahoulia, Faiy H
  organization: Laboratory of Signal Mediated Gene Expression, Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, 48 Vasileos Konstantinou Avenue, Athens 11635, Greece
– sequence: 2
  givenname: Konstantinos G
  surname: Drosopoulos
  fullname: Drosopoulos, Konstantinos G
– sequence: 3
  givenname: Lenka
  surname: Doubravska
  fullname: Doubravska, Lenka
– sequence: 4
  givenname: Ladislav
  surname: Andera
  fullname: Andera, Ladislav
– sequence: 5
  givenname: Alexander
  surname: Pintzas
  fullname: Pintzas, Alexander
BackLink https://www.ncbi.nlm.nih.gov/pubmed/17876056$$D View this record in MEDLINE/PubMed
BookMark eNpFkE1v4yAQhlHVVdOvn9CKU_fkFmyDybGKuruVUq22yh0RGGIqx7iAVeW2P724jtQLg5hn3kHPBTrtfQ8I3VByTykTD5RVrGgor-5fVpuCNAUhhJ6g8_wuCsFoffp1n5kFuojxLQNiWdIztKCNaDhh_Bz9_zdC0JBcj6FvVa8h4s3r4_O62INxKoHBavBD8tFFnCHtO5_PCQxYQ9dFvD3khhm163c4tYCV1uN-7FRymfQWG1CpxQE05JjwldK5wRkclE3xCv2wqotwfayXaPPrabP6U6z__n5ePa4LXROWCsbrrea6bmxtKSy3zFBVNoJazbmqtVCmtGVlOKtMTYm1VlsmDDG1VawxqrpEd3PsEPz7CDHJvYvT_1UPfoySizIrEWUG2Qzq4GMMYOUQ3F6Fg6RETublZFVOVmU2L0kjJ_N57va4YNxmdd9TR9UZ-DkDrdu1Hy6AnC0GiKCCbiWXS1myJa0-AYpIkbM
CitedBy_id crossref_primary_10_1038_sj_bjc_6605794
crossref_primary_10_1093_carcin_bgq220
crossref_primary_10_1002_glia_22345
crossref_primary_10_5012_jkcs_2015_59_2_136
crossref_primary_10_1002_cai2_99
crossref_primary_10_4993_acrt_29_96
crossref_primary_10_1186_s12885_018_4959_4
crossref_primary_10_1007_s00018_010_0407_6
crossref_primary_10_3892_ijo_2014_2795
crossref_primary_10_1016_j_fct_2013_08_085
crossref_primary_10_1007_s10495_012_0759_5
crossref_primary_10_1007_s13402_014_0183_7
crossref_primary_10_1097_MCO_0b013e32831394b8
crossref_primary_10_3390_molecules25225319
crossref_primary_10_2174_1389557519666191009152007
crossref_primary_10_1016_j_bbamem_2014_01_021
crossref_primary_10_18632_oncotarget_14675
crossref_primary_10_1007_s12038_012_9198_2
crossref_primary_10_1371_journal_pone_0016241
crossref_primary_10_1002_biof_1112
crossref_primary_10_1016_j_bcp_2008_12_027
crossref_primary_10_3892_ijo_2012_1748
crossref_primary_10_1016_j_ejmech_2017_12_039
crossref_primary_10_1016_j_jff_2016_06_004
crossref_primary_10_3390_ph13110342
crossref_primary_10_1016_j_febslet_2009_02_014
crossref_primary_10_1155_2019_9051542
crossref_primary_10_1016_j_biopha_2019_109604
crossref_primary_10_1097_CAD_0000000000000213
crossref_primary_10_1016_j_lfs_2010_07_004
crossref_primary_10_1016_j_micron_2021_103152
crossref_primary_10_1002_med_20123
crossref_primary_10_3389_fphar_2022_860209
crossref_primary_10_3892_etm_2015_2536
crossref_primary_10_1016_j_mam_2009_12_002
crossref_primary_10_1111_nure_12051
crossref_primary_10_1016_j_freeradbiomed_2013_05_039
crossref_primary_10_1016_j_jff_2013_11_002
crossref_primary_10_1155_2013_731940
crossref_primary_10_1007_s10495_009_0397_8
crossref_primary_10_1039_C4MD00268G
crossref_primary_10_3109_10715762_2012_690514
crossref_primary_10_1128_AAC_03599_14
crossref_primary_10_1371_journal_pone_0107165
crossref_primary_10_1002_med_21985
crossref_primary_10_1016_j_biotechadv_2015_12_014
crossref_primary_10_4161_cbt_19600
crossref_primary_10_1038_cddis_2012_29
crossref_primary_10_1177_1178223417749855
crossref_primary_10_1007_s00249_011_0786_0
crossref_primary_10_1002_ptr_5402
crossref_primary_10_1016_j_canlet_2008_03_046
crossref_primary_10_1016_j_canlet_2010_11_001
crossref_primary_10_1016_S1002_0721_12_60346_9
crossref_primary_10_1186_s12885_016_2606_5
crossref_primary_10_1016_j_cellsig_2023_110667
crossref_primary_10_1002_1873_3468_12863
crossref_primary_10_1007_s13318_023_00843_7
crossref_primary_10_13045_acupunct_2014027
crossref_primary_10_1155_2013_757628
crossref_primary_10_1097_CMR_0000000000000447
crossref_primary_10_1002_jcp_26640
crossref_primary_10_2174_1871520621666210624110547
crossref_primary_10_18632_oncotarget_2091
crossref_primary_10_1080_10408398_2020_1815171
crossref_primary_10_2174_1389201021666200226093202
crossref_primary_10_18632_oncotarget_6295
crossref_primary_10_33393_dti_2020_2185
crossref_primary_10_1016_j_lfs_2010_01_008
crossref_primary_10_1038_gene_2015_31
crossref_primary_10_3390_cancers11121948
crossref_primary_10_1002_jcp_28777
crossref_primary_10_1039_c2nr32181e
crossref_primary_10_13181_mji_v25i3_1449
crossref_primary_10_3390_cells12242840
crossref_primary_10_3390_ijms231911746
crossref_primary_10_1080_10408398_2017_1344186
crossref_primary_10_1038_srep24049
crossref_primary_10_1258_ebm_2011_011004
crossref_primary_10_5352_JLS_2009_19_9_1209
crossref_primary_10_1002_ijc_26323
crossref_primary_10_3390_ijms19123787
crossref_primary_10_18632_oncotarget_3073
crossref_primary_10_1007_s00018_016_2164_7
crossref_primary_10_1097_CAD_0000000000000095
crossref_primary_10_3389_fphar_2017_00015
crossref_primary_10_2174_0929867330666230301121611
crossref_primary_10_1021_jm801001d
crossref_primary_10_1038_onc_2012_164
crossref_primary_10_1089_ars_2012_4573
crossref_primary_10_1016_j_bcp_2023_115907
crossref_primary_10_1016_j_acthis_2016_11_003
crossref_primary_10_1371_journal_pone_0054577
crossref_primary_10_1016_j_jare_2021_11_008
crossref_primary_10_3109_10408363_2011_631268
crossref_primary_10_1038_cddis_2012_55
crossref_primary_10_7314_APJCP_2015_16_2_465
crossref_primary_10_1155_2017_4357165
crossref_primary_10_1155_2021_3157867
crossref_primary_10_3389_fphar_2017_00109
crossref_primary_10_1007_s10620_010_1191_8
crossref_primary_10_1007_s00018_016_2321_z
crossref_primary_10_1016_j_ejca_2012_03_005
crossref_primary_10_1016_j_jchromb_2014_01_005
crossref_primary_10_3390_biom9110679
crossref_primary_10_3892_etm_2013_1285
crossref_primary_10_1016_j_drup_2015_02_001
crossref_primary_10_1002_jcp_26595
crossref_primary_10_1088_1757_899X_991_1_012107
crossref_primary_10_1093_nar_gku1131
crossref_primary_10_1016_j_cytogfr_2013_12_009
crossref_primary_10_1016_j_bbrc_2009_08_016
crossref_primary_10_1021_la801471e
crossref_primary_10_2174_1570193X16666190723112623
crossref_primary_10_1080_01635581_2021_1900301
crossref_primary_10_1007_s00262_009_0732_5
crossref_primary_10_1111_febs_12347
crossref_primary_10_1016_j_bbrc_2013_08_040
crossref_primary_10_1093_carcin_bgp334
crossref_primary_10_3109_07357900902744486
crossref_primary_10_3390_ijms13077886
crossref_primary_10_3390_molecules26123483
crossref_primary_10_1194_jlr_TR119000439
crossref_primary_10_3390_molecules26051315
crossref_primary_10_1016_j_bcp_2020_113923
Cites_doi 10.1016/S0092-8674(00)81590-1
10.1016/S1074-7613(00)80211-3
10.1038/sj.onc.1207970
10.1074/jbc.272.43.26953
10.1038/sj.onc.1202568
10.1093/embo-reports/kvf022
10.1093/ajcn/81.1.243S
10.1038/35008667
10.1158/1535-7163.MCT-05-0086
10.1016/S0014-5793(99)01544-6
10.1158/1078-0432.CCR-05-2365
10.1038/sj.cdd.4401088
10.1158/0008-5472.CAN-05-1494
10.1038/sj.onc.1206127
10.1074/jbc.M412483200
10.1038/sj.leu.2402338
10.1016/j.drup.2005.02.003
10.1074/jbc.271.22.12687
10.1126/science.277.5327.768
10.1016/S0092-8674(01)00472-X
10.1038/sj.onc.1206493
10.1038/sj.onc.1207520
10.1016/j.ejca.2004.12.020
10.1038/sj.onc.1208086
10.1002/jcb.21098
10.1093/carcin/bgl232
10.1038/nrc821
10.1038/35036052
10.1158/0008-5472.CAN-03-3648
10.1002/(SICI)1097-0215(20000201)85:3<438::AID-IJC22>3.0.CO;2-F
10.1038/sj.bjc.6601707
10.1016/0168-9525(93)90209-Z
10.1038/ni1024
10.1074/jbc.M605934200
10.1093/emboj/17.6.1675
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1158/1535-7163.MCT-07-0001
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1538-8514
EndPage 2599
ExternalDocumentID 10_1158_1535_7163_MCT_07_0001
17876056
6_9_2591
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID -
08R
123
2WC
34G
39C
53G
55
5RE
5VS
AAPBV
ABFLS
ABOCM
ACIWK
ACPRK
ADACO
ADBBV
ADBIT
AENEX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
GX1
H13
H~9
IH2
KQ8
L7B
MVM
O0-
OK1
P2P
RCR
RHF
RHI
WOQ
X7M
ZA5
---
.55
18M
2FS
3O-
AAJMC
ACGFO
ADCOW
AFHIN
BR6
BTFSW
CGR
CUY
CVF
ECM
EIF
NPM
QTD
TR2
W8F
WHG
YBU
ZGI
ZXP
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c405t-564bc6c47f4f1e9b5d1a2781fc66a4c8ad2f23d653d410fffcf58d0d4fa57da3
ISSN 1535-7163
IngestDate Fri Oct 25 02:18:35 EDT 2024
Fri Aug 23 03:44:29 EDT 2024
Sat Sep 28 07:52:50 EDT 2024
Fri Jan 15 19:23:15 EST 2021
IsPeerReviewed true
IsScholarly true
Issue 9
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c405t-564bc6c47f4f1e9b5d1a2781fc66a4c8ad2f23d653d410fffcf58d0d4fa57da3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 17876056
PQID 68287682
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_68287682
crossref_primary_10_1158_1535_7163_MCT_07_0001
pubmed_primary_17876056
highwire_cancerresearch_6_9_2591
ProviderPackageCode RHF
RHI
PublicationCentury 2000
PublicationDate 20070901
2007-Sep
2007-09-01
PublicationDateYYYYMMDD 2007-09-01
PublicationDate_xml – month: 09
  year: 2007
  text: 20070901
  day: 01
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Molecular cancer therapeutics
PublicationTitleAlternate Mol Cancer Ther
PublicationYear 2007
Publisher American Association for Cancer Research
Publisher_xml – name: American Association for Cancer Research
References 2022060804494485900_BIB9
2022060804494485900_BIB8
2022060804494485900_BIB7
2022060804494485900_BIB6
2022060804494485900_BIB5
2022060804494485900_BIB4
2022060804494485900_BIB3
2022060804494485900_BIB2
2022060804494485900_BIB21
2022060804494485900_BIB1
2022060804494485900_BIB22
2022060804494485900_BIB20
2022060804494485900_BIB25
2022060804494485900_BIB26
2022060804494485900_BIB23
2022060804494485900_BIB24
2022060804494485900_BIB29
2022060804494485900_BIB27
2022060804494485900_BIB28
2022060804494485900_BIB10
2022060804494485900_BIB32
2022060804494485900_BIB11
2022060804494485900_BIB33
2022060804494485900_BIB30
2022060804494485900_BIB31
2022060804494485900_BIB14
2022060804494485900_BIB36
2022060804494485900_BIB15
2022060804494485900_BIB37
2022060804494485900_BIB12
2022060804494485900_BIB34
2022060804494485900_BIB13
2022060804494485900_BIB35
2022060804494485900_BIB18
2022060804494485900_BIB19
2022060804494485900_BIB16
2022060804494485900_BIB38
2022060804494485900_BIB17
References_xml – ident: 2022060804494485900_BIB3
– ident: 2022060804494485900_BIB13
  doi: 10.1016/S0092-8674(00)81590-1
– ident: 2022060804494485900_BIB22
  doi: 10.1016/S1074-7613(00)80211-3
– ident: 2022060804494485900_BIB23
  doi: 10.1038/sj.onc.1207970
– ident: 2022060804494485900_BIB10
  doi: 10.1074/jbc.272.43.26953
– ident: 2022060804494485900_BIB9
  doi: 10.1038/sj.onc.1202568
– ident: 2022060804494485900_BIB16
  doi: 10.1093/embo-reports/kvf022
– ident: 2022060804494485900_BIB27
  doi: 10.1093/ajcn/81.1.243S
– ident: 2022060804494485900_BIB11
  doi: 10.1038/35008667
– ident: 2022060804494485900_BIB36
  doi: 10.1158/1535-7163.MCT-05-0086
– ident: 2022060804494485900_BIB30
  doi: 10.1016/S0014-5793(99)01544-6
– ident: 2022060804494485900_BIB26
  doi: 10.1158/1078-0432.CCR-05-2365
– ident: 2022060804494485900_BIB31
  doi: 10.1038/sj.cdd.4401088
– ident: 2022060804494485900_BIB37
  doi: 10.1158/0008-5472.CAN-05-1494
– ident: 2022060804494485900_BIB19
  doi: 10.1038/sj.onc.1206127
– ident: 2022060804494485900_BIB20
  doi: 10.1074/jbc.M412483200
– ident: 2022060804494485900_BIB21
  doi: 10.1038/sj.leu.2402338
– ident: 2022060804494485900_BIB34
  doi: 10.1016/j.drup.2005.02.003
– ident: 2022060804494485900_BIB8
  doi: 10.1074/jbc.271.22.12687
– ident: 2022060804494485900_BIB2
– ident: 2022060804494485900_BIB14
  doi: 10.1126/science.277.5327.768
– ident: 2022060804494485900_BIB38
  doi: 10.1016/S0092-8674(01)00472-X
– ident: 2022060804494485900_BIB6
  doi: 10.1038/sj.onc.1206493
– ident: 2022060804494485900_BIB25
  doi: 10.1038/sj.onc.1207520
– ident: 2022060804494485900_BIB32
  doi: 10.1016/j.ejca.2004.12.020
– ident: 2022060804494485900_BIB18
  doi: 10.1038/sj.onc.1208086
– ident: 2022060804494485900_BIB7
  doi: 10.1002/jcb.21098
– ident: 2022060804494485900_BIB5
  doi: 10.1093/carcin/bgl232
– ident: 2022060804494485900_BIB15
  doi: 10.1038/nrc821
– ident: 2022060804494485900_BIB33
  doi: 10.1038/35036052
– ident: 2022060804494485900_BIB28
  doi: 10.1158/0008-5472.CAN-03-3648
– ident: 2022060804494485900_BIB29
– ident: 2022060804494485900_BIB4
  doi: 10.1002/(SICI)1097-0215(20000201)85:3<438::AID-IJC22>3.0.CO;2-F
– ident: 2022060804494485900_BIB24
  doi: 10.1038/sj.bjc.6601707
– ident: 2022060804494485900_BIB1
  doi: 10.1016/0168-9525(93)90209-Z
– ident: 2022060804494485900_BIB17
  doi: 10.1038/ni1024
– ident: 2022060804494485900_BIB35
  doi: 10.1074/jbc.M605934200
– ident: 2022060804494485900_BIB12
  doi: 10.1093/emboj/17.6.1675
SSID ssj0018921
Score 2.3426425
Snippet Cytokines such as tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) can induce apoptosis in colon cancer cells through engagement of death...
Cytokines such as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis in colon cancer cells through engagement of death...
Abstract Cytokines such as tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) can induce apoptosis in colon cancer cells through engagement of...
SourceID proquest
crossref
pubmed
highwire
SourceType Aggregation Database
Index Database
Publisher
StartPage 2591
SubjectTerms Adenocarcinoma - drug therapy
Adenocarcinoma - metabolism
Adenocarcinoma - pathology
apoptosis
Apoptosis - drug effects
BH3 Interacting Domain Death Agonist Protein - metabolism
Caspases - drug effects
Caspases - metabolism
colon
Colonic Neoplasms - drug therapy
Colonic Neoplasms - metabolism
Colonic Neoplasms - pathology
Cytochromes c - metabolism
Cytosol - drug effects
Cytosol - metabolism
Death Domain Receptor Signaling Adaptor Proteins - metabolism
Flow Cytometry
Fluorescent Antibody Technique
Humans
Immunoblotting
Immunoprecipitation
lipid rafts
Membrane Microdomains - drug effects
Membrane Microdomains - metabolism
Mitochondria - drug effects
Mitochondria - metabolism
quercetin
Quercetin - pharmacology
Receptors, TNF-Related Apoptosis-Inducing Ligand - metabolism
Receptors, Tumor Necrosis Factor - metabolism
TNF-Related Apoptosis-Inducing Ligand - pharmacology
TRAIL
Tumor Cells, Cultured - drug effects
Title Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts
URI http://mct.aacrjournals.org/content/6/9/2591.abstract
https://www.ncbi.nlm.nih.gov/pubmed/17876056
https://search.proquest.com/docview/68287682
Volume 6
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZB2MvY_dlVz3sLTiLbUm2H0PX0K1Jtw4X-iZkySKhrR1iu9A97W_s3-5IviWQscuLSRRHIvo-jr7jnAtC76mrXTcIiSN9whwCB5YT-glzqEqJngitlG3ftjhlx-fk8wW9GAx-bkUtVWUylt_35pX8D6owBriaLNl_QLabFAbgNeALV0AYrn-F8VllwlJKU_UjWxr4ilH8bfpp7th8EKMlxTpfl7kpOmLjza8Aa2lu3IzME_vCiE9wyivZJk0JKavrpqOX0ZHKKMQRWMV0bdvywCxXq_VKjTZC1zWgWmW7aPvstgtsZXZ1uv1rIZamBbtVrDOxuu1zIz5uTEcF-LCO-zupdSv8trzo-3-B3Afv_qa4tBPM0-yyO1WmJkunHhZqBUS_2XmgEXQRW70Npg64cf62kWZbXIy2DS6tm301hze8jfYfDNQkO3RTj69laYNuJ83KO4W4T7_w2fl8zuOji_gOuuuBDTPG8-Ss_4MqjLymFG89YZMcBst82LvIruxpS1H_3q2x8iZ-iB40fgme1iR7hAZp9hjdWzSRF0_Qj45ruOUa3uUa7riG4SbLNVxTAVuu4eQWt1zDQA68zTWca2y5hjuumVks17Dl2lMUz47iw2On6d7hSHACSocykkgmSaCJdtMoocoVXhC6WjImiAyF8rTnK0Z9RdyJ1lpqGqqJIlrQQAn_GTrI8ix9gbAfEZl4KpUe9UgQsQS8CpH4grkqTLTnDtG43Vu-rmu0cOvb0pAbMLgBgy8OYz6pgy2GCLcI8HojmspaS854xA2nhuhdiwwHg2v2SWRpXhWcmRYRcBmi5zVg_Zpw-DFwKF7-8buv0P2e-a_RQbmp0jcgbsvkraXZL7oaqtM
link.rule.ids 315,783,787,27936,27937
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Quercetin+enhances+TRAIL-mediated+apoptosis+in+colon+cancer+cells+by+inducing+the+accumulation+of+death+receptors+in+lipid+rafts&rft.jtitle=Molecular+cancer+therapeutics&rft.au=Psahoulia%2C+Faiy+H&rft.au=Drosopoulos%2C+Konstantinos+G&rft.au=Doubravska%2C+Lenka&rft.au=Andera%2C+Ladislav&rft.date=2007-09-01&rft.issn=1535-7163&rft.volume=6&rft.issue=9&rft.spage=2591&rft.epage=2599&rft_id=info:doi/10.1158%2F1535-7163.mct-07-0001&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1535-7163&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1535-7163&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1535-7163&client=summon